| Demographic Characteristics and Transmission Risk Factors of Patients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial | Yusuf Yılmaz, Mehmet Demir, Göktuğ Şirin, Şükran Köse, Orhan Sezgin, Selma Tosun, Meral Akdoğan, Şua Sümer, ilkay bozkurt, HAMDI LEVENT DOGANAY, Iftihar Koksal, Fehmi Tabak, RAHMET GÜNER, EMİNE PARLAK, DİLARA İNAN, Murat Aladağ, FIRDEVS TOPAL, Ayse Batirel, Reşit Mıstık, Behice Kurtaran, Ebubekir Se | 109–117 |
| Distribution of Hepatitis C Virus Genotypes: 18-Year Experience in an Academic Center | Kurtulus Buruk, NESE KAKLIKKAYA, Esra Özkaya, Faruk Aydın, Ilknur Tosun, Irmak Baran | 118–123 |
| The Treatment of Ledipasvir/Sofosbuvir in Patients with Chronic Hepatitis C Virus: The Results of Five-year Follow-up | Nevin Ince, Murat Pekgöz | 124–130 |
| Effect of Hepatitis B Virus Genotypes and Viral Load on the Response of Patients Treated with Peginterferon-α-2a | Muhammad Asim Anwar, Muhammad Naseem Hasrat, Majid Mahmood, Zahid Azam | 131–135 |
| Knowledge Level of Physicians in Turkey about Hepatitis C and New Treatments | Kadriye Kart Yaşar, Ayşegül İnci Sezen | 136–141 |
| Tenofovir Disoproxil Fumarate in the Management of Chronic Hepatitis B Infection in Children | Asuman Nur KARHAN, Ersin GÜMÜŞ, Hayriye HIZARCIOĞLU GÜLŞEN, Hülya DEMİR, İnci Nur SALTIK | 142–147 |
| Effect of a Nationwide Universal HBV Vaccination Program and Catch-up Vaccination Campaign on HBV Prevalence in Children | Selma TOSUN, Erhun KASIRGA, Serol DEVECİ | 148–152 |
| Molecular Analysis of Hepatitis B Virus Reverse Transcriptase Domain for Mutations Associated with Viral Resistance in Pakistani Patients | Zia Ur RAHMAN, Majid MAHMOOD, Muhammad Asim ANWAR, Sdia JAMEEL | 153–158 |
| Glecaprevir/Pibrentasvir Treatment in a Patient with Hemophilia and Mixed Genotype Hepatitis C Infection | Emine Füsun KARAŞAHİN, Ömer KARAŞAHİN | 159–161 |